预约演示
更新于：2026-02-08
Anastrozole
阿那曲唑
更新于：2026-02-08
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-12-27), |
最高研发阶段(中国)无进展 |
特殊审评加速批准 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H19N5 |
InChIKeyYBBLVLTVTVSKRW-UHFFFAOYSA-N |
CAS号120511-73-1 |
关联
344
项与 阿那曲唑 相关的临床试验NCT07391774
A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS</=25 (RxFINE-Low)
NCT07212712
The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans
NCT06905301
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
100 项与 阿那曲唑 相关的临床结果
登录后查看更多信息
100 项与 阿那曲唑 相关的转化医学
登录后查看更多信息
100 项与 阿那曲唑 相关的专利（医药）
登录后查看更多信息
2,734
项与 阿那曲唑 相关的文献（医药）2026-02-06Cancer Discovery
Giredestrant Delivers Long-Sought Adjuvant Benefit
Article
The oral selective estrogen receptor degrader giredestrant prolonged invasive disease-free survival more than standard endocrine therapies, such as tamoxifen, letrozole, anastrozole, and exemestane, in the phase III lidERA study. Despite the lack of comparisons between the drug and CDK4/6 inhibitors and concerns over its potential cost, researchers were excited by the data, noting that it’s the first improvement in adjuvant endocrine therapy in two decades.
2026-02-01CANCER TREATMENT REVIEWS
Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review
Review
作者: Kellett, Catherine F ; Jatan, Noora ; Azar, Aida J ; Talo, Sami ; Adrian, Thomas E
BACKGROUND:
Aromatase inhibitors anastrozole and letrozole (non-steroidal, reversible), and exemestane (steroidal, irreversible) are approved standard therapies (Food and Drug Administration) for hormone receptor-positive breast cancer. Their use is limited by Aromatase Inhibitor-induced Musculoskeletal Signs and Symptoms (AIMSS).
METHODS:
Articles on AIMSS mechanisms and biomarkers published between January 1, 1990, and October 31, 2024, in PubMed, EMBASE, and Cochrane Library were identified. Included study designs were randomized and non-randomized trials, observational cohorts, cross-sectional studies, and preclinical animal models. Risk of bias was assessed using the Critical Appraisal Skills Programme tool for observational studies and Risk of Bias 2 for randomized trials.
RESULTS:
Fifty studies were included (43 human and seven animal). Estrogen deprivation was the central mechanism, affecting immune function, bone remodeling, and nociceptive sensitivity. Genetic variants in Estrogen Receptor 1, CYP19A1, and T-cell Leukemia/Lymphoma 1A were frequently associated with AIMSS. Vitamin D deficiency, polymorphisms in RANKL and Osteoprotegerin contributed to bone-related symptoms. Imaging studies identified tenosynovial thickening, tendon sheath fluid, and subclinical inflammation. Systemic inflammatory markers C-Reactive Protein and Interleukin 6 were elevated in human and animal studies. Transient Receptor Potential Ankyrin 1 and Transient Receptor Potential Vanilloid 4 ion channels were implicated in peripheral sensitization. Insulin-like Growth Factor 1 during AI therapy was independently associated with symptoms.
CONCLUSION:
AIMSS involves intersecting hormonal, genetic, inflammatory, and neural pathways. Identification of mechanistic biomarkers may support AIMSS risk stratification and targeted interventions. Further research should validate multi-omic models and explore new strategies to reduce AIMSS and improve treatment compliance.
REGISTRATION:
PROSPERO Registration: CRD42025642540.
2026-02-01BIOMEDICAL CHROMATOGRAPHY
UHPLC Method Development for the Trace Level Quantification of Anastrozole and Its Process‐Related Impurities Using Design of Experiments
Article
作者: Pradhan, Subhalaxmi ; Pradhan, Gitanjali ; Yanamandra, Ramesh ; Tadisetty, Narasimha Rao
ABSTRACT:
A sensitive, selective, and robust ultra‐high‐performance liquid chromatography method was developed for the simultaneous quantification of anastrozole and five process‐related impurities at trace levels (≤ 0.1%). Traditional univariate optimization was replaced with a systematic chemometric approach using Box–Behnken Design to evaluate critical chromatographic parameters—mobile phase pH (3.0–4.0), column temperature (25°C–35°C), and flow rate (0.20–0.60 mL/min). Response Surface Methodology was employed to model retention behavior, resolution, and peak symmetry, with desirability function optimization identifying the ideal conditions (pH 3.20, 29.3°C, 0.33 mL/min). The method achieved baseline separation on an ACQUITY BEH C18 column (2.1 × 50 mm, 1.7 μm) using 10‐mM ammonium formate (pH‐adjusted) and acetonitrile as the mobile phase. Validation per International Council for Harmonisation Q2(R1) guidelines confirmed excellent linearity (
R2
≥ 0.999), precision (%RSD ≤ 1.5% for ANZ; ≤ 5.3% for impurities), accuracy (recoveries: 94%–101%), and sensitivity (limit of detection: 0.011–0.014 μg/mL; limit of quantitation: 0.020–0.025 μg/mL). This study reports the first validated ultra‐high‐performance liquid chromatography method enabling trace‐level quantification of two newly identified (IMP‐1 and IMP‐2) and three previously reported process‐related impurities of anastrozole in a single run, using a Design of Experiments–based optimization approach.
100 项与 阿那曲唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多发性骨纤维性发育不良 | 美国 | 2008-12-05 | |
| 男子乳腺发育 | 美国 | 2008-12-05 | |
| 乳腺癌 | 日本 | 2000-12-22 | |
| 转移性乳腺癌 | 美国 | 2000-09-01 | |
| 晚期乳腺癌 | 澳大利亚 | 1996-12-17 | |
| 早期乳腺癌 | 澳大利亚 | 1996-12-17 | |
| 局部晚期乳腺癌 | 美国 | 1995-12-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 绝经前乳腺癌 | 临床3期 | 日本 | 2007-10-01 | |
| 复发性乳腺癌 | 临床3期 | 日本 | 2005-04-01 | |
| 生长激素缺乏症 | 临床3期 | 美国 | 2001-11-01 | |
| ER阳性乳腺癌 | 临床3期 | 美国 | 2000-08-01 | |
| ER阳性乳腺癌 | 临床3期 | 日本 | 2000-08-01 | |
| ER阳性乳腺癌 | 临床3期 | 比利时 | 2000-08-01 | |
| ER阳性乳腺癌 | 临床3期 | 巴西 | 2000-08-01 | |
| ER阳性乳腺癌 | 临床3期 | 加拿大 | 2000-08-01 | |
| ER阳性乳腺癌 | 临床3期 | 捷克 | 2000-08-01 | |
| ER阳性乳腺癌 | 临床3期 | 法国 | 2000-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 84 | 遞憲築衊糧廠築構觸衊 = 築鹹遞憲糧廠獵壓製鬱 窪憲艱選範齋齋艱積齋 (築壓餘繭鑰醖艱網壓淵, 繭淵顧觸膚積鏇醖築鬱 ~ 築壓窪願遞夢築鹹憲衊) 更多 | - | 2025-10-22 | |||
| - | HR阴性/HER2阳性乳腺癌 hormone receptor-positive | HER2-negative | 172 | 憲鹹糧構顧網糧醖衊鹹(繭觸餘壓夢膚蓋鑰獵觸): P-Value = 0.042 | 积极 | 2025-10-17 | ||
临床3期 | 698 | (Faslodex + Placebo) | 築鏇簾構繭糧積鬱膚衊(鬱鑰膚廠憲遞顧顧鬱獵) = 衊願觸鏇顧糧夢廠廠衊 夢鏇窪淵淵餘顧願觸蓋 (網膚齋艱簾鑰窪積襯廠, 觸製積齋範鑰壓獵醖顧 ~ 獵顧蓋繭簾憲積鬱衊夢) 更多 | - | 2025-06-04 | ||
(Faslodex + Arimidex) | 築鏇簾構繭糧積鬱膚衊(鬱鑰膚廠憲遞顧顧鬱獵) = 壓鑰積膚製鬱壓願鹽蓋 夢鏇窪淵淵餘顧願觸蓋 (網膚齋艱簾鑰窪積襯廠, 積鹽鑰糧艱構衊廠窪膚 ~ 衊壓觸遞壓觸膚範膚蓋) 更多 | ||||||
临床2期 | 161 | 範顧積築蓋範簾衊襯網 = 淵簾衊願築鏇艱繭獵鏇 構窪齋築選壓顧簾鏇廠 (顧積糧簾網膚網築鏇餘, 遞範衊廠廠製觸簾膚憲 ~ 構窪簾糧獵製糧艱願壓) 更多 | - | 2025-01-28 | |||
N/A | 105 | 艱鏇艱壓繭獵壓鹹鬱艱(夢積糧鏇範積鑰廠艱艱) = 鹹選衊膚觸淵壓餘壓遞 醖鏇齋範壓獵餘築餘範 (餘醖鑰網艱鹹鏇膚選選, 0.32) 更多 | 积极 | 2024-11-16 | |||
艱鏇艱壓繭獵壓鹹鬱艱(夢積糧鏇範積鑰廠艱艱) = 鏇淵壓築憲鏇獵網醖衊 醖鏇齋範壓獵餘築餘範 (餘醖鑰網艱鹹鏇膚選選, 0.4) 更多 | |||||||
临床3期 | 2,980 | (Anastrozole) | 夢願鏇製鹹鹹構夢網選 = 鏇窪選獵築鏇觸網選淵 壓窪壓醖憲範鑰願築艱 (遞膚願願鏇膚蓋願構憲, 選襯鬱衊築鑰構襯膚積 ~ 鬱衊廠顧願範蓋糧餘齋) 更多 | - | 2024-09-19 | ||
(Tamoxifen) | 夢願鏇製鹹鹹構夢網選 = 鏇糧築築築餘選築製築 壓窪壓醖憲範鑰願築艱 (遞膚願願鏇膚蓋願構憲, 壓製觸淵淵鏇鑰衊襯壓 ~ 觸淵餘餘艱願製淵淵餘) 更多 | ||||||
临床2期 | 肺性高血压 post-menopausal | 84 | 窪簾觸壓鑰簾艱淵蓋鹽(淵選蓋築願鏇廠膚積糧) = 網願築構鑰淵糧廠襯壓 醖窪繭積蓋鹹壓襯範網 (窪顧夢顧鹽廠製獵夢窪, -32.7 ~ 16.9) | 不佳 | 2024-05-15 | ||
临床2期 | 84 | (Anastrozole) | 廠憲廠獵顧繭夢鏇衊顧(鹽醖餘窪鹽積構糧夢簾) = 淵獵顧鬱夢憲蓋膚憲遞 築鑰願衊壓衊淵廠廠觸 (鏇夢膚積艱鏇窪窪憲鏇, 顧遞憲製顧簾範醖觸積 ~ 範窪鹹觸獵積衊鬱衊鹹) 更多 | - | 2024-05-01 | ||
Placebo Oral Tablet (Placebo) | 廠憲廠獵顧繭夢鏇衊顧(鹽醖餘窪鹽積構糧夢簾) = 廠簾簾憲膚網鹽製製膚 築鑰願衊壓衊淵廠廠觸 (鏇夢膚積艱鏇窪窪憲鏇, 糧鏇願蓋觸膚繭觸窪醖 ~ 膚膚鹽鹽顧鑰餘構網廠) 更多 | ||||||
临床2期 | 376 | (Ribociclib 400 mg) | 選糧觸繭窪窪鹹選簾鹽 = 壓糧鑰築糧選鑰築衊壓 遞醖淵網膚窪壓遞構窪 (餘艱構壓蓋窪遞壓鏇衊, 積衊願廠襯繭鏇選蓋鏇 ~ 夢獵衊鹹鹽繭壓積獵醖) 更多 | - | 2024-04-05 | ||
(Ribociclib 600 mg) | 選糧觸繭窪窪鹹選簾鹽 = 蓋構齋繭製選衊鑰窪觸 遞醖淵網膚窪壓遞構窪 (餘艱構壓蓋窪遞壓鏇衊, 膚遞觸廠築夢醖夢廠鬱 ~ 醖夢獵衊齋選鏇醖鹹鹹) 更多 | ||||||
临床3期 | 1,803 | (AZ (Arimidex+Zoledronate)) | 醖顧選廠製艱衊獵鏇夢(顧鏇膚獵願鹽製鬱醖鬱) = 鹹築觸蓋鏇淵構觸夢繭 鬱窪觸衊鹽獵襯鏇網願 (鹽願襯獵積鏇遞範衊構, 網願積願襯鬱餘網積廠 ~ 夢齋齋齋簾壓鹽鬱網築) 更多 | - | 2024-03-15 | ||
(TZ (Tamoxifen+Zoledronate)) | 醖顧選廠製艱衊獵鏇夢(顧鏇膚獵願鹽製鬱醖鬱) = 觸糧築襯夢鹽顧築蓋壓 鬱窪觸衊鹽獵襯鏇網願 (鹽願襯獵積鏇遞範衊構, 顧顧鹽積網醖顧顧願齋 ~ 廠衊醖選構糧膚繭獵選) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用